Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of NovoEight in Relation to BMI in Haemophilia A
NCT02941354Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of turoctocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Plasma FVIII activity at 30 minutes. Started Oct 2016; status: completed.
02
Drugs
turoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02941354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941354.